BioSpace News Archive

Nimbus Therapeutics today announced it has entered into a research collaboration and exclusive, worldwide license agreement with Eli Lilly and Company (Lilly) for the development and commercialization of novel targeted therapies that activate a specific isoform of AMPK for the treatment of metabolic diseases.

AtriCure, Inc. today announced that it will release its third quarter 2022 financial results on Tuesday, November 1, 2022.

Aulos Bioscience today announced that initial safety data from patients who received monotherapy treatment in the Phase 1/2 trial of AU-007 will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

Xenetic Biosciences, Inc. today announced the signing of a patent assignment from CLS Therapeutics, Inc. (“CLS”) to Xenetic related to Xenetic’s previously announced collaboration with VolitionRx Limited (NYSE AMERICAN:VNRX) (“Volition”), a multi-national epigenetics company, and CLS, a biopharmaceutical company developing first-in-class therapies based on the discovery of novel therapeutic targets.

Viewpoint Molecular Targeting, Inc. today announced the award of two additional Small Business Innovation Research (SBIR) phase II grants totaling $4 million.

Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, today announced that it will present on GLIMMER-01, the ongoing Phase 1/2 Trial of its lead program E-602 Bi-Sialidase at the Society for Immunotherapy of Cancer’s 37th Annual Meeting taking place in Boston from November 8-12, 2022.

NorthStar Medical Radioisotopes, LLC and Eckert & Ziegler Isotope Technologies Dresden announced an agreement for the purchase of hot cells and related equipment for NorthStar’s dedicated non-carrier-added actinium-225 production facility.

EpiVario, a biotech company developing novel therapeutics for memory-related psychiatric disorders, announced that Anthony Ford-Hutchinson, PhD, and Paul Kenny, PhD, have been appointed to the Company’s Scientific Advisory Board.

ReddyPort, a NIV-focused medical technology company, announced today that US Patent No 11,324,910 has been issued by the US Patent Office covering Positive Pressure Ventilation Appliance Modules and Related Systems and Methods.

Great Bay Bio (hereinafter referred to as “GBB”) today announces the official launch of its self-developed AI-enabled site-specific integration platform for cell line development (CLD), AlfaCell®.